1
|
Bönisch H, Fink KB, Malinowska B, Molderings GJ, Schlicker E. Serotonin and beyond-a tribute to Manfred Göthert (1939-2019). NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY 2021; 394:1829-1867. [PMID: 33991216 PMCID: PMC8376721 DOI: 10.1007/s00210-021-02083-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/23/2021] [Accepted: 03/29/2021] [Indexed: 01/13/2023]
Abstract
Manfred Göthert, who had served Naunyn-Schmiedeberg's Arch Pharmacol as Managing Editor from 1998 to 2005, deceased in June 2019. His scientific oeuvre encompasses more than 20 types of presynaptic receptors, mostly on serotoninergic and noradrenergic neurones. He was the first to identify presynaptic receptors for somatostatin and ACTH and described many presynaptic receptors, known from animal preparations, also in human tissue. In particular, he elucidated the pharmacology of presynaptic 5-HT receptors. A second field of interest included ligand-gated and voltage-dependent channels. The negative allosteric effect of anesthetics at peripheral nACh receptors is relevant for the peripheral clinical effects of these drugs and modified the Meyer-Overton hypothesis. The negative allosteric effect of ethanol at NMDA receptors in human brain tissue occurred at concentrations found in the range of clinical ethanol intoxication. Moreover, the inhibitory effect of gabapentinoids on P/Q Ca2+ channels and the subsequent decrease in AMPA-induced noradrenaline release may contribute to their clinical effect. Another ligand-gated ion channel, the 5-HT3 receptor, attracted the interest of Manfred Göthert from the whole animal via isolated preparations down to the cellular level. He contributed to that molecular study in which 5-HT3 receptor subtypes were disclosed. Finally, he found altered pharmacological properties of 5-HT receptor variants like the Arg219Leu 5-HT1A receptor (which was also shown to be associated with major depression) and the Phe124Cys 5-HT1B receptor (which may be related to sumatriptan-induced vasospasm). Manfred Göthert was a brilliant scientist and his papers have a major impact on today's pharmacology.
Collapse
Affiliation(s)
- H Bönisch
- Institute of Pharmacology and Toxicology, University of Bonn, Venusberg-Campus 1, 53105, Bonn, Germany
| | - K B Fink
- Merz Pharmaceuticals, Frankfurt/Main, Germany
| | - B Malinowska
- Department of Physiology and Pathophysiology, Medical University of Białystok, Białystok, Poland
| | - G J Molderings
- Institute of Human Genetics, University of Bonn, Bonn, Germany
| | - E Schlicker
- Institute of Pharmacology and Toxicology, University of Bonn, Venusberg-Campus 1, 53105, Bonn, Germany.
| |
Collapse
|
2
|
Bruzzone C, Gil-Redondo R, Seco M, Barragán R, de la Cruz L, Cannet C, Schäfer H, Fang F, Diercks T, Bizkarguenaga M, González-Valle B, Laín A, Sanz-Parra A, Coltell O, de Letona AL, Spraul M, Lu SC, Buguianesi E, Embade N, Anstee QM, Corella D, Mato JM, Millet O. A molecular signature for the metabolic syndrome by urine metabolomics. Cardiovasc Diabetol 2021; 20:155. [PMID: 34320987 PMCID: PMC8320177 DOI: 10.1186/s12933-021-01349-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/13/2021] [Accepted: 07/19/2021] [Indexed: 12/12/2022] Open
Abstract
Background Metabolic syndrome (MetS) is a multimorbid long-term condition without consensual medical definition and a diagnostic based on compatible symptomatology. Here we have investigated the molecular signature of MetS in urine. Methods We used NMR-based metabolomics to investigate a European cohort including urine samples from 11,754 individuals (18–75 years old, 41% females), designed to populate all the intermediate conditions in MetS, from subjects without any risk factor up to individuals with developed MetS (4–5%, depending on the definition). A set of quantified metabolites were integrated from the urine spectra to obtain metabolic models (one for each definition), to discriminate between individuals with MetS. Results MetS progression produces a continuous and monotonic variation of the urine metabolome, characterized by up- or down-regulation of the pertinent metabolites (17 in total, including glucose, lipids, aromatic amino acids, salicyluric acid, maltitol, trimethylamine N-oxide, and p-cresol sulfate) with some of the metabolites associated to MetS for the first time. This metabolic signature, based solely on information extracted from the urine spectrum, adds a molecular dimension to MetS definition and it was used to generate models that can identify subjects with MetS (AUROC values between 0.83 and 0.87). This signature is particularly suitable to add meaning to the conditions that are in the interface between healthy subjects and MetS patients. Aging and non-alcoholic fatty liver disease are also risk factors that may enhance MetS probability, but they do not directly interfere with the metabolic discrimination of the syndrome. Conclusions Urine metabolomics, studied by NMR spectroscopy, unravelled a set of metabolites that concomitantly evolve with MetS progression, that were used to derive and validate a molecular definition of MetS and to discriminate the conditions that are in the interface between healthy individuals and the metabolic syndrome. Supplementary Information The online version contains supplementary material available at 10.1186/s12933-021-01349-9.
Collapse
Affiliation(s)
- Chiara Bruzzone
- Precision Medicine and Metabolism Laboratory, CIC bioGUNE, BRTA, CIBERehd, Bizkaia Technology Park, Bld. 800, 48160, Derio, Bizkaia, Spain
| | - Rubén Gil-Redondo
- Precision Medicine and Metabolism Laboratory, CIC bioGUNE, BRTA, CIBERehd, Bizkaia Technology Park, Bld. 800, 48160, Derio, Bizkaia, Spain
| | - Marisa Seco
- OSARTEN Kooperativa Elkartea, 20500, Arrasate-Mondragón, Spain
| | - Rocío Barragán
- Department of Preventive Medicine and Public Health, School of Medicine, University of Valencia, 46010, Valencia, Spain.,CIBER Fisiopatología de la Obesidad y Nutrición, Madrid, Spain
| | - Laura de la Cruz
- Precision Medicine and Metabolism Laboratory, CIC bioGUNE, BRTA, CIBERehd, Bizkaia Technology Park, Bld. 800, 48160, Derio, Bizkaia, Spain
| | - Claire Cannet
- Bruker Biospin GmbH, Silberstreifen, 76287, Rheinstetten, Germany
| | - Hartmut Schäfer
- Bruker Biospin GmbH, Silberstreifen, 76287, Rheinstetten, Germany
| | - Fang Fang
- Bruker Biospin GmbH, Silberstreifen, 76287, Rheinstetten, Germany
| | - Tammo Diercks
- Precision Medicine and Metabolism Laboratory, CIC bioGUNE, BRTA, CIBERehd, Bizkaia Technology Park, Bld. 800, 48160, Derio, Bizkaia, Spain
| | - Maider Bizkarguenaga
- Precision Medicine and Metabolism Laboratory, CIC bioGUNE, BRTA, CIBERehd, Bizkaia Technology Park, Bld. 800, 48160, Derio, Bizkaia, Spain
| | - Beatriz González-Valle
- Precision Medicine and Metabolism Laboratory, CIC bioGUNE, BRTA, CIBERehd, Bizkaia Technology Park, Bld. 800, 48160, Derio, Bizkaia, Spain
| | - Ana Laín
- Precision Medicine and Metabolism Laboratory, CIC bioGUNE, BRTA, CIBERehd, Bizkaia Technology Park, Bld. 800, 48160, Derio, Bizkaia, Spain
| | - Arantza Sanz-Parra
- Precision Medicine and Metabolism Laboratory, CIC bioGUNE, BRTA, CIBERehd, Bizkaia Technology Park, Bld. 800, 48160, Derio, Bizkaia, Spain
| | - Oscar Coltell
- CIBER Fisiopatología de la Obesidad y Nutrición, Madrid, Spain.,Department of Computer Languages and Systems, Universitat Jaume I, 12071, Castellón, Spain
| | | | - Manfred Spraul
- Bruker Biospin GmbH, Silberstreifen, 76287, Rheinstetten, Germany
| | - Shelly C Lu
- Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | | | - Nieves Embade
- Precision Medicine and Metabolism Laboratory, CIC bioGUNE, BRTA, CIBERehd, Bizkaia Technology Park, Bld. 800, 48160, Derio, Bizkaia, Spain
| | - Quentin M Anstee
- Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.,Newcastle NIHR Biomedical Research Centre, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK
| | - Dolores Corella
- Department of Preventive Medicine and Public Health, School of Medicine, University of Valencia, 46010, Valencia, Spain.,CIBER Fisiopatología de la Obesidad y Nutrición, Madrid, Spain
| | - José M Mato
- Precision Medicine and Metabolism Laboratory, CIC bioGUNE, BRTA, CIBERehd, Bizkaia Technology Park, Bld. 800, 48160, Derio, Bizkaia, Spain
| | - Oscar Millet
- Precision Medicine and Metabolism Laboratory, CIC bioGUNE, BRTA, CIBERehd, Bizkaia Technology Park, Bld. 800, 48160, Derio, Bizkaia, Spain.
| |
Collapse
|
3
|
Zhou X, He D, Yan X, Chen X, Li R, Zhang G, Wang J. Moxonidine inhibits excitatory inputs to airway vagal preganglionic neurons via activation of both α 2-adrenoceptors and imidazoline I1 receptors. Brain Res 2020; 1732:146695. [PMID: 32007398 DOI: 10.1016/j.brainres.2020.146695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2019] [Revised: 12/26/2019] [Accepted: 01/29/2020] [Indexed: 10/25/2022]
Abstract
As an imidazoline I1 receptor agonist with very weak binding affinity for α2-adrenoceptors, moxonidine is commonly used in the treatment of hypertension. Moxonidine also has been implicated to act centrally to reduce airway vagal outflow. However, it is unknown at which central sites moxonidine acts to affect airway vagal activity, and how moxonidine takes effect at synaptic and receptor levels. In this study, airway vagal preganglionic neurons (AVPNs) were retrogradely labeled in neonatal rats from the intrathoracic trachea; retrogradely labeled AVPNs in the external formation of the nucleus ambiguus (NA) were identified in rhythmically active medullary slices using whole-cell patch-clamp techniques; and the effects of moxonidine on the spontaneous excitatory postsynaptic currents (EPSCs) of AVPNs were observed at synaptic level. The results show that moxonidine (10 μmol·L-1) significantly inhibited the frequency of spontaneous EPSCs in both inspiratory-activated and inspiratory-inhibited AVPNs. This effect was partially blocked by SKF-86466 (10 μmol·L-1), a highly selective antagonist of α2-adrenoceptors, or AGN-192403, a selective antagonist of imidazoline I1 receptors, and was completely blocked by efaroxan (10 μmol·L-1), an antagonist of both α2-adrenoceptors and imidazoline I1 receptors. These results demonstrate that moxonidine inhibits the excitatory inputs to AVPNs via activation of both α2-adrenoceptors and imidazoline I1 receptors, and suggest that physiologically both of these two types of receptors are involved in the central regulation of airway vagal activity at preganglionic level. Moxonidine might be potentially useful in diseases with aberrant airway vagal activity such as asthma and chronic obstructive diseases.
Collapse
Affiliation(s)
- Xujiao Zhou
- Eye Institute in Eye & ENT Hospital, and NHC Key Laboratory of Myopia, Fudan University, China; Shanghai Key Laboratory of Visual Impairment and Restoration, China; Key Laboratory of Myopia, Chinese Academy of Medical Sciences, China
| | - Ding He
- Department of Physiology and Pathophysiology, Fudan University School of Basic Medical Sciences, China
| | - Xianxia Yan
- Department of Physiology and Pathophysiology, Fudan University School of Basic Medical Sciences, China
| | - Xingxin Chen
- Department of Physiology and Pathophysiology, Fudan University School of Basic Medical Sciences, China
| | - Rui Li
- Department of Nursing, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China
| | - Guangming Zhang
- Department of Anesthesiology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China.
| | - Jijiang Wang
- Department of Physiology and Pathophysiology, Fudan University School of Basic Medical Sciences, China.
| |
Collapse
|
4
|
Guanabenz repurposed as an antiparasitic with activity against acute and latent toxoplasmosis. Antimicrob Agents Chemother 2015; 59:6939-45. [PMID: 26303803 DOI: 10.1128/aac.01683-15] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2015] [Accepted: 08/20/2015] [Indexed: 11/20/2022] Open
Abstract
Toxoplasma gondii is a protozoan parasite that persists as a chronic infection. Toxoplasma evades immunity by forming tissue cysts, which reactivate to cause life-threatening disease during immune suppression. There is an urgent need to identify drugs capable of targeting these latent tissue cysts, which tend to form in the brain. We previously showed that translational control is critical during infections with both replicative and latent forms of Toxoplasma. Here we report that guanabenz, an FDA-approved drug that interferes with translational control, has antiparasitic activity against replicative stages of Toxoplasma and the related apicomplexan parasite Plasmodium falciparum (a malaria agent). We also found that inhibition of translational control interfered with tissue cyst biology in vitro. Toxoplasma bradyzoites present in these abnormal cysts were diminished and misconfigured, surrounded by empty space not seen in normal cysts. These findings prompted analysis of the efficacy of guanabenz in vivo by using established mouse models of acute and chronic toxoplasmosis. In addition to protecting mice from lethal doses of Toxoplasma, guanabenz has a remarkable ability to reduce the number of brain cysts in chronically infected mice. Our findings suggest that guanabenz can be repurposed into an effective antiparasitic with a unique ability to reduce tissue cysts in the brain.
Collapse
|
5
|
Nguyen PH, Hammoud H, Halliez S, Pang Y, Evrard J, Schmitt M, Oumata N, Bourguignon JJ, Sanyal S, Beringue V, Blondel M, Bihel F, Voisset C. Structure-activity relationship study around guanabenz identifies two derivatives retaining antiprion activity but having lost α2-adrenergic receptor agonistic activity. ACS Chem Neurosci 2014; 5:1075-82. [PMID: 25244284 DOI: 10.1021/cn5001588] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
Guanabenz (GA) is an orally active α2-adrenergic agonist that has been used for many years for the treatment of hypertension. We recently described that GA is also active against both yeast and mammalian prions in an α2-adrenergic receptor-independent manner. These data suggest that this side-activity of GA could be explored for the treatment of prion-based diseases and other amyloid-based disorders. In this perspective, the potent antihypertensive activity of GA happens to be an annoying side-effect that could limit its use. In order to get rid of GA agonist activity at α2-adrenergic receptors, we performed a structure-activity relationship study around GA based on changes of the chlorine positions on the benzene moiety and then on the modifications of the guanidine group. Hence, we identified the two derivatives 6 and 7 that still possess a potent antiprion activity but were totally devoid of any agonist activity at α2-adrenergic receptors. Similarly to GA, 6 and 7 were also able to inhibit the protein folding activity of the ribosome (PFAR) which has been suggested to be involved in prion appearance/maintenance. Therefore, these two GA derivatives are worth being considered as drug candidates.
Collapse
Affiliation(s)
- Phu hai Nguyen
- Inserm UMR 1078, Université de Bretagne Occidentale, Faculté de Médecine et des Sciences de la Santé;
Etablissement Français du Sang (EFS) Bretagne; CHRU Brest,
Hôpital Morvan, Laboratoire de Génétique Moléculaire, 29200 Brest, France
| | - Hassan Hammoud
- Laboratoire d’Innovation
Thérapeutique, UMR7200, CNRS, Université de Strasbourg, Faculté
de pharmacie, 74, route
du Rhin, 67400 Illkirch, France
| | - Sophie Halliez
- Virologie
Immunologie Moléculaires, UR892, Institut National de la Recherche Agronomique (INRA), 78352 Jouy-en-Josas, France
| | - Yanhong Pang
- Department
of Cell and Molecular Biology, Box-596, BMC, Uppsala University, 751 05 Uppsala, Sweden
| | - Justine Evrard
- Inserm UMR 1078, Université de Bretagne Occidentale, Faculté de Médecine et des Sciences de la Santé;
Etablissement Français du Sang (EFS) Bretagne; CHRU Brest,
Hôpital Morvan, Laboratoire de Génétique Moléculaire, 29200 Brest, France
| | - Martine Schmitt
- Laboratoire d’Innovation
Thérapeutique, UMR7200, CNRS, Université de Strasbourg, Faculté
de pharmacie, 74, route
du Rhin, 67400 Illkirch, France
| | - Nassima Oumata
- Laboratoire
de Chimie Organique 2, Inserm U1022, Université Paris Descartes, 75006 Paris, France
| | - Jean-Jacques Bourguignon
- Laboratoire d’Innovation
Thérapeutique, UMR7200, CNRS, Université de Strasbourg, Faculté
de pharmacie, 74, route
du Rhin, 67400 Illkirch, France
| | - Suparna Sanyal
- Department
of Cell and Molecular Biology, Box-596, BMC, Uppsala University, 751 05 Uppsala, Sweden
| | - Vincent Beringue
- Virologie
Immunologie Moléculaires, UR892, Institut National de la Recherche Agronomique (INRA), 78352 Jouy-en-Josas, France
| | - Marc Blondel
- Inserm UMR 1078, Université de Bretagne Occidentale, Faculté de Médecine et des Sciences de la Santé;
Etablissement Français du Sang (EFS) Bretagne; CHRU Brest,
Hôpital Morvan, Laboratoire de Génétique Moléculaire, 29200 Brest, France
| | - Frédéric Bihel
- Laboratoire d’Innovation
Thérapeutique, UMR7200, CNRS, Université de Strasbourg, Faculté
de pharmacie, 74, route
du Rhin, 67400 Illkirch, France
| | - Cécile Voisset
- Inserm UMR 1078, Université de Bretagne Occidentale, Faculté de Médecine et des Sciences de la Santé;
Etablissement Français du Sang (EFS) Bretagne; CHRU Brest,
Hôpital Morvan, Laboratoire de Génétique Moléculaire, 29200 Brest, France
| |
Collapse
|
6
|
Adjuvant therapy with intrathecal clonidine improves postoperative pain in patients undergoing coronary artery bypass graft. Clin J Pain 2009; 25:101-6. [PMID: 19333153 DOI: 10.1097/ajp.0b013e3181817add] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
BACKGROUND Alpha2 adrenergic agonists have long been employed as analgesics and to sedate patients undergoing surgical procedures. In addition, their therapeutic response synergizes that elicited by opioids. Although this response is well known, the role of alpha2 agonists, such as clonidine, during various painful surgical procedures remains to be elucidated. The goal of our study was to evaluate the effects of the intrathecal administration of clonidine on postoperative pain control and time to extubation in patients undergoing coronary artery bypass grafting. METHODS Eighty-five patients undergoing coronary artery bypass grafting randomly received either an intrathecal injection of preservative free morphine 0.5 mg (MOR) or a combination of morphine 0.5 mg and clonidine 100 microg (CMC) before induction of anesthesia. Anesthesia was induced and maintained using a balanced anesthesia technique. Patients were transferred to the intensive care unit while intubated and weaned from mechanical ventilation following an established weaning protocol. Postoperative pain, opioid use within the first 24 hours, and time to extubation were used as primary outcome variables. Data were analyzed by a 2-tailed t test for continuous variables and Fisher exact test for nonparametric variables. RESULTS There were no demographic differences between the CMC and MOR groups. Postoperative pain, as assessed by a visual analog scale, was milder in the CMC group when compared with that of the MOR group (2.2+/-0.36 vs. 3.4+/-0.33, P<0.05). Similarly, patients in the CMC group required lower doses of morphine within 24 hours compared with the MOR group (2.02+/-0.36 vs. 6.47+/-0.49 mg, P<0.0001). Time to extubation was significantly shorter in patients receiving CMC than in those who received MOR (592+/-52 vs. 887+/-75 min, P<0.05). There was no mortality in either group. There was a trend for increased vasopressin use in the CMC group compared with the MOR group, although this was not statistically significant (P=0.07). CONCLUSIONS Addition of clonidine to neuraxial opioids improves the quality of analgesia postoperatively and expedites the process of weaning from mechanical ventilation. There were no serious adverse events in the cohort of the patients studied. However, the safety profile of this medication remains to be examined with a larger group of patients.
Collapse
|
7
|
Tribouillard-Tanvier D, Béringue V, Desban N, Gug F, Bach S, Voisset C, Galons H, Laude H, Vilette D, Blondel M. Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions. PLoS One 2008; 3:e1981. [PMID: 18431471 PMCID: PMC2291559 DOI: 10.1371/journal.pone.0001981] [Citation(s) in RCA: 92] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2007] [Accepted: 03/10/2008] [Indexed: 11/24/2022] Open
Abstract
BACKGROUND Prion-based diseases are incurable transmissible neurodegenerative disorders affecting animals and humans. METHODOLOGY/PRINCIPAL FINDINGS Here we report the discovery of the in vivo antiprion activity of Guanabenz (GA), an agonist of alpha2-adrenergic receptors routinely used in human medicine as an antihypertensive drug. We isolated GA in a screen for drugs active in vivo against two different yeast prions using a previously described yeast-based two steps assay. GA was then shown to promote ovine PrP(Sc) clearance in a cell-based assay. These effects are very specific as evidenced by the lack of activity of some GA analogues that we generated. GA antiprion activity does not involve its agonist activity on alpha2-adrenergic receptors as other chemically close anti-hypertensive agents possessing related mechanism of action were found inactive against prions. Finally, GA showed activity in a transgenic mouse-based in vivo assay for ovine prion propagation, prolonging slightly but significantly the survival of treated animals. CONCLUSION/SIGNIFICANCE GA thus adds to the short list of compounds active in vivo in animal models for the treatment of prion-based diseases. Because it has been administrated for many years to treat hypertension on a daily basis, without major side-effects, our results suggest that it could be evaluated in human as a potential treatment for prion-based diseases.
Collapse
Affiliation(s)
- Déborah Tribouillard-Tanvier
- INSERM U613, Brest, France
- Univ Brest, Faculté de Médecine et des Sciences de la Santé, UMR-S613, Brest, France
- Etablissement Français du Sang (EFS) Bretagne, Brest, France
- CHU Brest, Hop Morvan, Laboratoire de Génétique Moléculaire, Brest, France
- CNRS UPS2682, Station Biologique, Protein Phosphorylation and Disease Laboratory, Place Georges Teissier, Roscoff, France
| | - Vincent Béringue
- Institut National de la Recherche Agronomique (INRA), UR892, Virologie Immunologie Moléculaires, Jouy-en-Josas, France
| | - Nathalie Desban
- CNRS UPS2682, Station Biologique, Protein Phosphorylation and Disease Laboratory, Place Georges Teissier, Roscoff, France
| | - Fabienne Gug
- INSERM U648, Laboratoire de Chimie Organique 2, Université Paris Descartes, Paris, France
| | - Stéphane Bach
- CNRS UPS2682, Station Biologique, Protein Phosphorylation and Disease Laboratory, Place Georges Teissier, Roscoff, France
| | - Cécile Voisset
- INSERM U613, Brest, France
- Univ Brest, Faculté de Médecine et des Sciences de la Santé, UMR-S613, Brest, France
- Etablissement Français du Sang (EFS) Bretagne, Brest, France
- CHU Brest, Hop Morvan, Laboratoire de Génétique Moléculaire, Brest, France
| | - Hervé Galons
- INSERM U648, Laboratoire de Chimie Organique 2, Université Paris Descartes, Paris, France
| | - Hubert Laude
- Institut National de la Recherche Agronomique (INRA), UR892, Virologie Immunologie Moléculaires, Jouy-en-Josas, France
| | - Didier Vilette
- Institut National de la Recherche Agronomique (INRA), UR892, Virologie Immunologie Moléculaires, Jouy-en-Josas, France
| | - Marc Blondel
- INSERM U613, Brest, France
- Univ Brest, Faculté de Médecine et des Sciences de la Santé, UMR-S613, Brest, France
- Etablissement Français du Sang (EFS) Bretagne, Brest, France
- CHU Brest, Hop Morvan, Laboratoire de Génétique Moléculaire, Brest, France
| |
Collapse
|
8
|
Sharma V, Tepe JJ. Diastereochemical Diversity of Imidazoline Scaffolds via Substrate Controlled TMSCl Mediated Cycloaddition of Azlactones. Org Lett 2005; 7:5091-4. [PMID: 16235965 DOI: 10.1021/ol052118w] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
[reaction: see text] We report herein a trimethylsilyl chloride mediated substrate controlled 1,3-dipolar cycloaddition for the diastereoselective synthesis of either syn- or anti-imidazolines. This method provides scaffolds with four points of diversity and control over two stereocenters.
Collapse
Affiliation(s)
- Vasudha Sharma
- Department of Chemistry, Michigan State University, East Lansing, 48823, USA
| | | |
Collapse
|
9
|
Cameron OG, Abelson JL, Young EA. Anxious and depressive disorders and their comorbidity: effect on central nervous system noradrenergic function. Biol Psychiatry 2004; 56:875-83. [PMID: 15576065 DOI: 10.1016/j.biopsych.2004.08.007] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/15/2004] [Revised: 07/07/2004] [Accepted: 08/19/2004] [Indexed: 11/19/2022]
Abstract
BACKGROUND Although comorbidity of anxiety with depression is common, investigations of physiologic abnormalities related specifically to comorbidity are rare. This study examined relationships of DSM-IV-defined depression, anxiety, and their comorbidity to noradrenergic function measured by blunting of the growth hormone (GH) response to the alpha2 adrenoreceptor agonist (and imidazoline receptor agent) clonidine and by blood pressure and symptom responses. METHODS Fifteen subjects with pure social anxiety or panic disorder, 15 with pure major depression, and 18 with both depression and anxiety were compared with healthy control subjects matched for age and gender. Other factors known to affect GH (weight, menstrual status, prior antidepressant, or other drug exposure) were controlled. RESULTS Anxiety produced GH blunting, but depression was associated with normal GH responses. The comorbid state did not affect results beyond the impact of anxiety. Preclonidine stress-related GH elevations were observed, to the greatest degree in anxious subjects. Relevant symptom, but not blood pressure, changes were significantly associated with blunting. CONCLUSIONS With use of pure depression and anxiety groups and careful control of other factors known to affect GH, these results demonstrate central nervous system noradrenergic dysfunction in anxiety disorders. In contrast to less rigorously controlled studies, noradrenergic function in depression was normal.
Collapse
Affiliation(s)
- Oliver G Cameron
- Department of Psychiatry, University of Michigan Medical Center, Ann Arbor, Michigan, USA.
| | | | | |
Collapse
|
10
|
Abstract
The I1-imidazoline receptor is a novel neurotransmitter receptor found mainly in the brainstem, adrenal medulla and kidney. The actions of moxonidine are described at the level of individual biomolecules, cells, tissues, organs and finally with integrative functions. The receptor functions at the cellular level works through arachidonic acid and phospholipid signaling cascades in neuronal cells with the net result of inhibiting sympathetic premotor neurons.
Collapse
Affiliation(s)
- P Ernsberger
- Department of Nutrition, Case Western University, School of Medicine Cleveland, Ohio 44106, USA
| |
Collapse
|
11
|
Csete K, Papp JG. Effects of moxonidine on corticocerebral blood flow under normal and ischemic conditions in conscious rabbits. J Cardiovasc Pharmacol 2000; 35:417-21. [PMID: 10710127 DOI: 10.1097/00005344-200003000-00011] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Hypertension associated with excessive liberation of circulating and tissue catecholamines is an independent risk factor for further cardiovascular complications and an important predictor of stroke. Moxonidine is a centrally acting anti-hypertensive drug with potent action on I1-imidazoline receptors. It inhibits catecholamine release and is therefore expected to exert an antiadrenergic effect at various levels in the regulation of the cardiovascular system. The aim of this study was to investigate the effect of moxonidine (0.025-0.1 mg/kg, i.v.) on the normal and unilateral carotid occlusion-induced impaired corticocerebral blood flow (cCBF) determined by hydrogen polarography, on mean arterial blood pressure (MABP) and heart rate (HR) in conscious rabbits. Moxonidine produced a reduction of MABP and HR. On the other hand, after administration of the drug, a significant increase in the normal and impaired cCBF was observed. Because the improvement in cCBF was conspicuous in both normal and ischemic conditions, moxonidine might be beneficial not only in the treatment of hypertension but also in the management of cerebral ischemia.
Collapse
Affiliation(s)
- K Csete
- Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical University, Hungarian Academy of Sciences, Szeged.
| | | |
Collapse
|
12
|
Hayar A, Guyenet PG. Prototypical imidazoline-1 receptor ligand moxonidine activates alpha2-adrenoceptors in bulbospinal neurons of the RVL. J Neurophysiol 2000; 83:766-76. [PMID: 10669492 DOI: 10.1152/jn.2000.83.2.766] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Moxonidine is an antihypertensive drug that lowers sympathetic vasomotor tone by stimulating either alpha2-adrenergic (alpha2-AR) or imidazoline I1 receptors within the rostral ventrolateral medulla (RVL). In this study, we investigated the effects of moxonidine (10 microM) on RVL neurons in brain stem slices of neonatal rats. We recorded mainly from retrogradely labeled RVL bulbospinal neurons (putative presympathetic neurons) except for some extracellular recordings. Prazosin was used to block alpha1-adrenoceptors. Moxonidine inhibited the extracellularly recorded discharges of all spontaneously active RVL neurons tested (bulbospinal and unidentified). This effect was reversed or blocked by the selective alpha2-AR antagonist SKF 86466 (10 microM). In contrast, the I1 imidazoline ligand AGN 192403 (10 microM) had no effect on the spontaneous activity. In whole cell recordings (holding potential -70 mV), moxonidine produced a small and variable outward current (mean 7 pA). This current was observed in both tyrosine hydroxylase-immunoreactive and other bulbospinal neurons and was blocked by SKF 86466. Excitatory postsynaptic currents (EPSCs) evoked by focal electrical stimulation were isolated by incubation with gabazine and strychnine, and inhibitory postsynaptic currents (IPSCs) were isolated with 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX). Moxonidine reduced the amplitude of the evoked EPSCs (EC(50) = 1 microM; 53% inhibition at 10 microM) but not their decay time constant (5.6 ms). The effect of moxonidine on EPSCs persisted in barium (300 microM) and was reduced approximately 80% by SKF 86466. Moxonidine also reduced the amplitude of evoked IPSCs by 63%. In conclusion, moxonidine inhibits putative RVL presympathetic neurons both presynaptically and postsynaptically. All observed effects in the present study are consistent with an alpha2-AR agonist activity of moxonidine.
Collapse
Affiliation(s)
- A Hayar
- Department of Pharmacology, University of Virginia, Charlottesville, Virginia 22908, USA
| | | |
Collapse
|
13
|
Smyth DD, Penner SB. Imidazoline receptor mediated natriuresis: central and/or peripheral effect? JOURNAL OF THE AUTONOMIC NERVOUS SYSTEM 1998; 72:155-62. [PMID: 9851564 DOI: 10.1016/s0165-1838(98)00100-3] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
The ability of imidazoline agonists, such as moxonidine and rilmenidine, to lower blood pressure has been attributed to a central effect resulting in a decrease in peripheral sympathetic nerve activity. A similar decrease in sympathetic nerve activity to the kidney has been proposed to explain the increase in sodium excretion. The observed increase in sodium excretion following an intrarenal infusion of moxonidine or rilmenidine suggested the existence of a direct renal action. We therefore tested the hypothesis that direct renal infusions were acting at a central rather than a peripheral site. Thus, interventions which would decrease the natriuretic effects of central administered moxonidine would also block the effects of intrarenal administered moxonidine. Studies were performed in anesthetized Sprague-Dawley rats (280-320 g) which had undergone unilateral nephrectomy 7 to 10 days prior to the experiment. The interventions utilized resulted in minimal effects on blood pressure and creatinine clearance. Intracerebroventricular (icv) or intrarenal (ir) administration of moxonidine produced a significant increase in urine flow rate and sodium excretion. Intravenous (iv) prazosin was used to block the ability of the sympathetic nerves to alter sodium excretion secondary to alpha1-adrenoceptor stimulation. Prazosin prevented the natriuresis following icv moxonidine but only partially antagonized the effects of ir moxonidine. To determine if central imidazoline receptors mediated the effects of moxonidine, animals were pretreated with icv idazoxan. Following icv idazoxan, the effects of icv moxonidine were blocked, whereas the response to intrarenal moxonidine was only partially blocked. Peripheral (iv) administration of idazoxan blocked the actions of intrarenal moxonidine but left the response to icv moxonidine intact. Finally, chemical sympathectomy with reserpine did not alter the response to intrarenal moxonidine suggesting that this effect was independent of the sympathetic nervous system. In conclusion, these studies indicate the ability of central and peripheral moxonidine to increase urine flow rate through sodium excretion at two unique sites of action, one central and the other one peripheral, most conceivably within the kidney.
Collapse
Affiliation(s)
- D D Smyth
- Department of Pharmacology, Faculty of Medicine, University of Manitoba, Winnipeg, Canada.
| | | |
Collapse
|
14
|
Wood DH, Hall JE, Rose BG, Tidwell RR. 1,5-Bis(4-amidinophenoxy)pentane (pentamidine) is a potent inhibitor of [3H]idazoxan binding to imidazoline I2 binding sites. Eur J Pharmacol 1998; 353:97-103. [PMID: 9721046 DOI: 10.1016/s0014-2999(98)00386-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
The aromatic diamidine 1,5-bis(4-amidinophenoxy)pentane (pentamidine) is used for treatment and prophylaxis of Pneumocystis carinii pneumonia in patients with Acquired Immune Deficiency Syndrome. Clinical use of pentamidine has been restricted by significant toxicity, that includes hypotension, and hypoglycemia. Although clinical toxicity is well described, the mechanisms are still poorly understood. Competitive binding analyses using [3H]idazoxan as the radioligand, and cirazoline to define non-specific binding, demonstrate that pentamidine binds to an imidazoline I2 binding site on rat liver membranes with a Ki of 1.4+/-0.22 nM. The Ki indicates that pentamidine inhibits radioligand binding at imidazoline I2 sites with an affinity approximating the most potent known ligands and may be related to pentamidine toxicity. Moreover, pentamidine analogs inhibit radioligand binding with a range of affinities that vary according to their structure. Two candidate drugs, Compounds 5 and 6, are more active than pentamidine in the corticosteroid-suppressed rat model of P. carinii pneumonia, yet have different affinities for the imidazoline I2 site (Ki 5 = 50.1+/-1.06 nM and Ki 6 = approximately 3500 nM). Affinity for this site does not correlate with antimicrobial activity (r = 0.60; p = 0.09) or the calculated log of the octanol:water partition coefficient (ClogP) (r = -0.38; p = 0.22).
Collapse
Affiliation(s)
- D H Wood
- Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, 27599, USA
| | | | | | | |
Collapse
|
15
|
Abstract
Stimulating cardiac beta 1-adrenoceptors with oxyfedrine causes dilatation of coronary vessels and positive inotropic effects on the myocardium. beta 1-adrenergic agonists increase coronary blood flow in nonstenotic and stenotic vessels. The main indication for the use of the phosphodiesterase inhibitors pamrinone, mirinone, enoximone and piroximone is acute treatment of severe congestive heart failure. Theophylline is indicated for the treatment of asthma, chronic obstructive pulmonary disease, apnea in preterm infants ans sleep apnea syndrome. Severe arterial occlusive disease associated with atherosclerosis can be beneficially affected by elcosanoids. These drugs must be administered parenterally and have a half-life of only a few minutes. Sublingual or buccal preparations of nitrates are the only prompt method (within 1 or 2 min) of terminating anginal pain, except for biting nifedipine capsules. The short half-life (about 2.5 min) of nitroglycerin (glyceryl trinitrate) makes long term therapy impossible. Tolerance is a problem encountered with longer-acting nitric oxide donors. Knowledge of the pharmacokinetic properties of vasodilating drugs can prevent a too sudden and severe blood pressure decrease in patients with chronic hypertension. In considering the administration of a second dose, or another drug, the time necessary for the initially administered drug to reach maximal efficacy should be taken into account. In hypertensive emergencies urapidil, sodium nitroprusside, nitroglycerin, hydralazine and phentolamine are the drugs of choice, with the addition of beta-blockers during catecholamine crisis or dissecting aortic aneurysm. Childhood hypertension is most often treated with angiotensin-converting enzyme (ACE) inhibitors or calcium antagonists, primarily nifedipine. Because of the teratogenic risk involved with ACE inhibitors, extreme caution must be exercised when prescribing for adolescent females. The propagation of health benefits to breast-fed infants, combined with more women delaying pregnancy until their fourth decade, has entailed an increase in the need for hypertension management during lactation. Low dose hydrochlorothiazide, propranolol, nifedipine and enalapril or captopril do not pose enough of a risk of preclude breastfeeding in this group. The most frequently used antihypertensive agents during pregnancy are methyldopa, labetalol and calcium channel antagonists. Methyldopa and beta-blockers are the drugs of choice for treating mild to moderate hypertension. Prazosin and hydralazine are used to treat moderate to severe hypertension and hydralazine, urapidil or labetalol are used to treat hypertensive emergencies. The use of overly aggressive antihypertensive therapy during pregnancy should be avoided so that adequate uteroplacental blood flow is maintained. Methyldopa is the only drug accepted for use during the first trimester of pregnancy.
Collapse
Affiliation(s)
- R Kirsten
- Department of Clinical Pharmacology, University of Frankfurt, Germany
| | | | | | | |
Collapse
|
16
|
Kawasaki H, Araki H, Futagami K, Gomita Y. Age-related decrease in centrally-mediated pressor response to clonidine in conscious rats. Brain Res 1998; 782:333-6. [PMID: 9519283 DOI: 10.1016/s0006-8993(97)01377-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
An age-related change in pressor response to intracerebroventricular (i.c.v.) injection of clonidine in conscious rats was investigated. In 15-week-old rats, clonidine (2 to 20 micrograms) caused a dose-dependent pressor response concomitant with decrease in heart rate. The depressor response to i.c.v. clonidine at lower doses (2 and 5 micrograms) but not higher doses (10 and 20 micrograms) was observed. The pressor response to clonidine in 20- and 30-week-old rats was markedly diminished, and the depressor response appeared at any of the doses injected. However, no age-related change in heart rate responses was observed. These results suggest that the centrally mediated pressor response to clonidine is age-related and masks the depressor response.
Collapse
Affiliation(s)
- H Kawasaki
- Department of Clinical Pharmaceutical Science, Faculty of Pharmaceutical Sciences, Okayama University, Japan.
| | | | | | | |
Collapse
|
17
|
Prichard BN, Graham BR. The use of moxonidine in the treatment of hypertension. JOURNAL OF HYPERTENSION. SUPPLEMENT : OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY OF HYPERTENSION 1997; 15:S47-55. [PMID: 9050986 DOI: 10.1097/00004872-199715011-00007] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
BACKGROUND Imidazoline I1-receptor agonism represents a new mode of antihypertensive action to inhibit peripheral alpha-adrenergic tone by a central mechanism. Adrenaline, noradrenaline and renin levels are reduced, a finding consistent with central inhibition of sympathetic tone. Acute haemodynamic studies indicate that moxonidine results in an acute decrease in blood pressure due to a fall in systemic vascular resistance, whereas the heart rate, cardiac output, stroke volume and pulmonary artery pressures are not affected. Left ventricular end systolic and diastolic volumes are reduced. Left ventricular hypertrophy has been found to regress after 6 months of treatment. PHARMACOKINETICS Following oral administration, maximum concentration is reached at about 1 h, and bioavailability approaches 90%. Moxonidine is mostly excreted unchanged, and biotransformation is unimportant. The half-life of moxonidine is 2.5 h, which is prolonged by renal insufficiency. However, the antihypertensive effect lasts longer than would be expected from the half-life, suggesting possible retention in the central nervous system. DRUG EFFECTS Decreases of about 20-30 mmHg systolic and 10-20 mmHg diastolic blood pressure have been found in open studies with moxonidine. The dosage of 0.2-0.4 mg moxonidine daily controls hypertension in most patients. Moxonidine has been compared with representatives from each important class of antihypertensive drugs, with clonidine, diuretics, both alpha- and beta-blocking drugs, calcium antagonists and angiotensin converting enzyme inhibitors. Blood pressure control has been observed to be similar with moxonidine and these other agents. Generally, the overall incidence of side-effects has been found to be similar, although the incidence of side-effects with clonidine is greater than that seen with moxonidine. CONCLUSIONS A meta-analysis of controlled studies with moxonidine found that moxonidine gave similar reductions in blood pressure in both men and women, in those aged below 50, 50-60 and over 60 years, and regardless of body weight. As often seen with some other drugs, higher systolic blood pressures are associated with larger reductions in systolic blood pressure and the same appears to be the case with diastolic blood pressure.
Collapse
Affiliation(s)
- B N Prichard
- Division of Clinical Pharmacology and Toxicology, University College London Medical School, UK
| | | |
Collapse
|